In the latest trading session,, 1.41 million Astrazeneca plc ADR (NASDAQ:AZN) shares changed hands as the company’s beta touched 0.37. With the company’s most recent per share price at $69.99 changing hands around $0.3 or 0.43% at last look, the market valuation stands at $217.06B. AZN’s current price is a discount, trading about -25.28% off its 52-week high of $87.68. The share price had its 52-week low at $61.24, which suggests the last value was 12.5% up since then. When we look at Astrazeneca plc ADR’s average trading volume, we note the 10-day average is 5.48 million shares, with the 3-month average coming to 6.07 million.
Analysts gave the Astrazeneca plc ADR (AZN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.34. If we narrow down to specifics, the data shows that 0 out of 10 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended AZN as a Hold, 8 felt it is a Buy and 0 rated the stock as Underweight.
Astrazeneca plc ADR (NASDAQ:AZN) trade information
Instantly AZN is in green as seen in intraday trades today. With action 3.35%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 6.82%, with the 5-day performance at 3.35% in the green. However, in the 30-day time frame, Astrazeneca plc ADR (NASDAQ:AZN) is 4.62% up. Looking at the short shares, we see there were 4.82 million shares sold at short interest cover period of 0.7 days.
The consensus price target for the stock as assigned by Wall Street analysts is 85, meaning bulls need an upside of 17.66% from its recent market value. According to analyst projections, AZN’s forecast low is 79 with 88 as the target high. To hit the forecast high, the stock’s price needs a -25.73% plunge from its current level, while the stock would need to soar -12.87% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 34.63%. The 2025 estimates are for Astrazeneca plc ADR earnings to increase by 9.83%, but the outlook for the next 5-year period is at 11.18% per year.
AZN Dividends
Astrazeneca plc ADR is expected to release its next quarterly earnings report on 2025-Apr-28. The 2.21% annual yield figure for the share gives it an annual dividend of 1.55. It is important to note, however, that the 2.21% dividend yield ratio should serve as a guide only, as you should also take into consideration many other aspects of a company’s operations and fundamentals before making any investment decision. During the past 5 years, the average dividend yield was 2.28 per year.
Astrazeneca plc ADR (NASDAQ:AZN)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.00% of Astrazeneca plc ADR shares while 17.21% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 17.21%. There are 17.21% institutions holding the Astrazeneca plc ADR stock share, with PRICE T ROWE ASSOCIATES INC /MD/ the top institutional holder. As of 2024-06-30, the company held 4.1788% of the shares, roughly 64.94 million AZN shares worth $5.06 billion.
PRIMECAP MANAGEMENT CO/CA/ holds the second largest percentage of outstanding shares, with 2.7411% or 42.6 million shares worth $3.32 billion as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund and WASHINGTON MUTUAL INVESTORS FUND . With 25.51 shares estimated at $1.79 billion under it, the former controlled 0.97% of total outstanding shares. On the other hand, WASHINGTON MUTUAL INVESTORS FUND held about 0.76% of the shares, roughly 20.06 shares worth around $1.4 billion.
